Tags

Type your tag names separated by a space and hit enter

Olmesartan medoxomil: current status of its use in monotherapy.
Vasc Health Risk Manag. 2006; 2(4):327-40.VH

Abstract

Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes.

Authors+Show Affiliations

Lausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, Switzerland. hrbrunner13@bluewin.ch

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17323586

Citation

Brunner, Hans R.. "Olmesartan Medoxomil: Current Status of Its Use in Monotherapy." Vascular Health and Risk Management, vol. 2, no. 4, 2006, pp. 327-40.
Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2(4):327-40.
Brunner, H. R. (2006). Olmesartan medoxomil: current status of its use in monotherapy. Vascular Health and Risk Management, 2(4), 327-40.
Brunner HR. Olmesartan Medoxomil: Current Status of Its Use in Monotherapy. Vasc Health Risk Manag. 2006;2(4):327-40. PubMed PMID: 17323586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Olmesartan medoxomil: current status of its use in monotherapy. A1 - Brunner,Hans R, PY - 2007/2/28/pubmed PY - 2007/3/31/medline PY - 2007/2/28/entrez SP - 327 EP - 40 JF - Vascular health and risk management JO - Vasc Health Risk Manag VL - 2 IS - 4 N2 - Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes. SN - 1176-6344 UR - https://www.unboundmedicine.com/medline/citation/17323586/Olmesartan_medoxomil:_current_status_of_its_use_in_monotherapy_ L2 - https://dx.doi.org/10.2147/vhrm.2006.2.4.327 DB - PRIME DP - Unbound Medicine ER -